Altered intercellular communication

Your cells are in constant chemical conversation, and with age that conversation fills with static: worn-out cells shout inflammatory noise, the physical lines between neighbours degrade, and the blood itself accumulates pro-aging messages. This is the hallmark that turns local cellular damage into whole-body decline — and one where some blood markers of inflammation have been shown, in randomised trials, to shift modestly with the ordinary levers of movement and diet.

Altered intercellular communication is the tenth of the twelve hallmarks of aging and one of the four integrative hallmarks — the system-wide consequences that emerge once upstream cellular damage has accumulated, alongside stem-cell exhaustion, chronic inflammation and dysbiosis.[1] Where the primary hallmarks describe damage inside cells, this one describes the breakdown of the signalling between them. A useful way to picture it is signal-to-noise: healthy tissue keeps its chemical messages clear, while aged tissue fills with background clutter that drowns out the cues cells depend on. One research group has measured a version of this directly, finding that the proteins made in older tissue become noisier as well as more abundant with age.[2]

How confident should you be

Descriptive — Moderate. Intervention — Weak; the two headline therapies are investigational, and one of them was run by people who sell it.

That signalling degrades with age is not in doubt, but this hallmark is rated more cautiously than most of the twelve for a specific reason: the evidence is largely correlative, and the most dramatic experiments — joining the circulations of young and old animals — are animal work; people cannot be joined to a younger partner, and the closest human tests, which remove plasma, are mostly small and point in different directions. To count as a hallmark at all, a process must meet three tests: it appears during normal aging, worsening it accelerates aging, and targeting it slows aging.[3] It is that third test this hallmark meets least convincingly, and the hallmarks framework page reaches the same verdict. What is well established is the description: senescent-cell secretions, decaying physical channels, a stiffening scaffold, pro-aging blood factors and a drifting hypothalamic clock. What is weak is any claim that a therapy reverses it in a healthy person.

One note on the numbers below. Where a result is followed by a range in parentheses — a 95% confidence interval — that range is where the true effect most plausibly lies. A wide range means the study could not pin the effect down; a range that includes zero means the result is compatible with no effect at all.

The main source of the noise: senescent cells and what they secrete

Moderate. The mechanism is well characterised; the systemic-spread step rests on cell and animal work.

The single largest contributor to age-related signalling noise is the senescent cell. Worn-out cells that have stopped dividing but refuse to die remain metabolically active and continuously secrete a pro-inflammatory cocktail — the senescence-associated secretory phenotype (SASP) — of inflammatory signalling proteins, chemical attractants for immune cells, and tissue-degrading enzymes.[4]

Two features make this a communication problem rather than a per-cell one. First, in cell and animal experiments, SASP factors push neighbouring healthy cells into "bystander" senescence. In mice, transplanting a relatively small number of senescent cells was enough to spread senescence into the host's own tissues and impair physical function.[5] Second, senescent cells package part of their cargo into extracellular vesicles, membrane-wrapped parcels that can push nearby and, in cell and mouse experiments, more distant cells toward senescence. Reviews propose that this may let the damage spread through the body, though some vesicles appear to lessen senescence rather than spread it, and the spread has not yet been shown directly in human tissue.[6]

The sustained output of these signals is what produces inflammaging — the chronic, sterile, low-grade inflammation that pervades aged tissue. The senescence machinery itself, and the drugs aimed at it, are covered in depth under cellular senescence; this article follows the other communication channels, which get far less attention.

The physical lines go down: gap junctions, nanotubes, and a stiffening matrix

Moderate as description. Each channel below is well characterised in cell and animal work; none rests on a human outcome trial.

Beyond the chemical broadcast, cells talk through direct physical connections — and these degrade in characteristic ways.

Gap junctions are membrane channels, built from connexin proteins, that let adjacent cells pass small signalling molecules — calcium ions, the cell's energy currency ATP, and a relay molecule called cyclic AMP — directly from one cytoplasm to the next. The age-related failure is subtle and easy to state backwards: the channels are still there, but they stop opening on cue. In bone-forming cells taken from old rats and grown in a dish, connexin levels hold steady, yet the cells fail to ramp up junctional communication when stimulated by parathyroid hormone. The authors trace this at least partly to a weaker cyclic-AMP response from the enzyme just upstream. They suggest the defect may contribute to age-related bone loss, but the study measured no bone in living animals, so the link to bone remodelling is a hypothesis rather than a demonstrated cause.[7] The downstream clinical picture is covered under bone density.

Tunneling nanotubes are long, thin bridges built from the cell's internal scaffolding protein, letting cells shuttle whole cargo — vesicles, even mitochondria — over surprising distances. They can be regenerative, ferrying healthy mitochondria to rescue a damaged neighbour. In lab studies, inflammation, oxidative stress, toxins and tissue injury make more of them form, and in cell-culture studies they can carry toxic protein clumps such as tau and alpha-synuclein from one neuron to the next.[8] Whether that happens in the living human brain, and how much it adds to the spread of Alzheimer's and Parkinson's pathology, has not been shown. The structures are fragile, have no specific marker and are easily confused with other cell protrusions, so a 2026 review calls for direct evidence from living tissue to pin down their role.[9]

The extracellular matrix stiffens. Cells sit in a protein scaffold — collagen and elastin — whose long-lived fibres accumulate chemical cross-links and sugar-driven damage over decades, making tissue progressively rigid. That stiffness is itself a signal. Cells sense how rigid their surroundings are, and one hypothesis, set out in a 2021 review, holds that a stiff, sugar-damaged matrix pushes them toward scarring (fibrotic) and senescent states, a mechanical feedback loop rather than a chemical one.[10] Reversing that stiffness has proved hard. Alagebrium, a drug designed to break sugar-driven cross-links, did not soften arteries in a year-long trial of 48 healthy, inactive adults around 70,[11] and it did not improve exercise capacity in 102 people with heart failure and a weakened heart pump.[12] Vitamin C and the amino acids from dietary protein are needed to build collagen in the first place, but there is no good evidence that getting more than enough undoes age-related cross-linking. The best human signal for less-stiff arteries comes from regular aerobic exercise done four to five days a week from middle age onward, and even that rests largely on comparisons between people rather than on trials.[13]

The blood carries the message

Moderate in animals. People cannot be joined to a younger partner; the closest human tests remove plasma, with or without replacing it, and they are mostly small, mostly track biomarkers rather than health, and point in different directions.

The most striking evidence that aging is partly a signalling phenomenon comes from blood-sharing experiments. In heterochronic parabiosis — surgically joining the circulations of a young and an old animal — the old animal's tissues partially rejuvenate, and this happens at some expense to the young one. The method has now produced a lifespan result. Old female mice joined to young partners for three months and then separated lived a median of about six weeks longer than old mice joined to old partners, and their blood and liver still tested epigenetically younger two months after separation.[14] A second lab using a similar three-month design found only a small gain in the old animals that was not statistically significant, while the young partners died sooner.[15] A cleaner version of the experiment, exchanging blood between young and old mice without joining their organs, affects muscle, liver and hippocampus within days, and it resolves the direction of the effect: in many tissues the inhibitory effect of old blood is larger than the benefit of young blood, and injury makes the negative effect worse.[16] Pro-aging signals in old blood actively suppress healthy function, in other words, rather than merely reflecting passive decline.

Old blood carries a recognisable set of pro-inflammatory proteins that rise with age. In mice, several of them (the chemokine CCL11, beta-2-microglobulin and TGF-beta1) have been shown to reduce the birth of new neurons and impair memory when young animals share an old animal's circulation.[17] The corollary — that removing or diluting these factors might restore regenerative capacity — is the rationale behind the plasma-exchange experiments below. This is also the biology that links social and psychological state to aging — chronic stress and isolation act on the same circulating immune-endocrine milieu, and the evidence for that link is laid out under purpose and stress.

The master clock drifts: neuroendocrine decline

Moderate as description; Weak for intervention — the reversal experiments are animal-only.

Long-range signalling is coordinated by the hypothalamus, the brain's master regulator of hormonal and autonomic function, and it ages in a way that ripples outward. In mice, a leading driver appears to be local neuroinflammation: aging activates inflammatory signalling in the hypothalamus's resident immune cells, which inflame neighbouring neurons and suppress the production of gonadotropin-releasing hormone (GnRH), the signal at the top of the reproductive hormone axis. Blocking that inflammation in the mouse hypothalamus slowed aging and lengthened life.[18] GnRH comes from a strikingly small group of cells, about 2,000 in the human hypothalamus; people also carry a much larger, recently discovered set of GnRH-making cells elsewhere in the brain, mostly in the basal ganglia, whose role is not yet understood.[19] In aging mice, the fall in GnRH went along with fewer new neurons in the hypothalamus and hippocampus and with thinner skin, weaker muscle and bone loss.[20] That whole cascade sits downstream of a broader age-related rewiring of hypothalamic signalling.[21] In old mice, GnRH delivered directly into the brain substantially restored the production of new neurons, and daily GnRH injections under the skin for five to eight weeks lessened the skin, muscle and bone changes. GnRH treatment was never tested for an effect on lifespan, and it has not been tested as an aging treatment in people.[22]

The same drift reaches other hormone systems. The pituitary's thyroid-stimulating signal (TSH) tends to creep up with age and the active thyroid hormone (T3) tends to fall, while the main circulating thyroid hormone (T4) usually holds steady. The daily cortisol rhythm flattens because evening cortisol stays high. It is still unsettled how much of this reflects aging itself rather than illness, eating less or medication, and how much it contributes to declining health in later life.[23] This is the mechanistic basis for the hub page's note that hormonal optimisation can be a lever when clinically indicated: menopausal hormone therapy in the critical window, testosterone therapy for symptomatic hypogonadism, and thyroid management. None of these is an anti-aging intervention for a person whose levels are normal. The thyroid case shows that the age-related drift itself is not a target: in a placebo-controlled trial of 737 adults aged 65 and over whose TSH was mildly raised but whose thyroid hormone was normal, a year of levothyroxine lowered TSH but improved neither symptoms nor tiredness.[24]

What you can do today

Moderate. Randomised trials show exercise, a Mediterranean diet and caloric restriction lower some blood markers of inflammation, and a large cohort with accelerometer-measured sleep and activity ties the same behaviours to longer, healthier lives; no trial has shown that lowering these markers slows aging itself.

The reassuring theme of this hallmark is that the signalling environment responds measurably to ordinary behaviour, and the three levers that matter are the familiar ones.

The best single piece of evidence that they belong together comes from a UK Biobank analysis of 59,078 adults (median age 64) whose sleep and activity were measured with wrist accelerometers rather than questionnaires, then followed for a median of 8.1 years. Comparing the most favourable third of the population on all three behaviours — 7.2 to 8.0 hours of sleep, more than 42 minutes of moderate-to-vigorous activity a day, and a high diet-quality score — against the least favourable third, the gap was about 9.4 additional years of life (95% CI 6.7–11.6) and a near-identical 9.5 additional years lived free of cardiovascular disease, cancer, type 2 diabetes, chronic obstructive pulmonary disease and dementia (95% CI 5.5–13.6).[25] Those are wide ranges, and this is an observational study modelling life expectancy rather than a trial — one whose senior author holds equity in a lifestyle-behaviour company. The direction and rough size are still hard to argue with.

The finding that made headlines is worth stating precisely, because the headlines did not. For someone starting in the worst 5% of the population — under six hours of sleep, a few minutes of activity a day, a poor diet — adding just five minutes of sleep, two minutes of activity and half a serving of vegetables a day, all at once, was associated with about one additional year of life (95% CI 0.7–1.2).[26] That is a genuine and encouraging result about how little it takes to move off the floor. It is not a claim that five minutes of sleep buys anyone a year: the figure is a statistical extrapolation from the cohort, not something measured in people who actually changed their habits. The authors did test whether the three behaviours together add up to more than the sum of their parts. They found a small extra boost for lifespan but none for years lived free of the five major diseases.[27] Those disease-free years also took bigger changes. In the same UK adults, starting from the same worst-5% baseline, about 24 more minutes of sleep, about 4 more minutes of moderate-to-vigorous activity a day and a clearly better diet were linked to roughly four extra disease-free years, with a wide margin of uncertainty.[28]

Exercise sends signals of its own. Contracting muscle releases exerkines — signalling molecules from muscle, liver and fat tissue, many packaged into the same kind of extracellular vesicles that carry senescent cargo — which travel to distant organs with anti-inflammatory and pro-regenerative messages, promoting mitochondrial biogenesis and insulin sensitivity.[29] Exercise appears to push the same circulatory channel that fills with pro-aging noise in the other direction, which is one reason physical activity touches so many of the hallmarks at once.[30] The human trials show the effect is real but modest. Pooling randomised trials of structured exercise in people aged 65 and over, training for 8 weeks to 12 months produced modest but statistically significant falls in C-reactive protein, the standard blood marker of low-grade inflammation, while results for other inflammatory messengers such as interleukin-6 and tumour necrosis factor alpha (TNF-alpha) were inconsistent, and many of the trials were at moderate to high risk of bias.[31] A separate pooling of 54 trials in about 2,800 adults aged 60 and over ranked aerobic training as giving the most consistent fall in C-reactive protein.[32] See zone 2 training and resistance training for the targets.

Sleep keeps the cellular clocks aligned. In mice, the core clock genes switch on daily production of NAMPT, the enzyme that recycles NAD⁺, so NAD⁺ rises and falls on a 24-hour cycle. NAD⁺ is a coenzyme cells need to run their repair and maintenance machinery, including the sirtuin enzymes that depend on it.[33] NAMPT and NAD⁺ fall with age, a changing daily rhythm is one of several suspected reasons, and falling NAD⁺ is one of the routes by which stressed cells tip toward senescence.[34] No study has yet shown directly that chronic short sleep or late-evening light lowers NAD⁺ this way in people. A small human experiment does link sleep loss to the senescence secretions themselves: in 29 community-dwelling adults aged 61 to 86, a single night with sleep allowed only from 3 to 7 a.m. raised the activity of senescence-associated secretion genes in their circulating immune cells. One senescence marker did not hold up on a confirmatory test, and the study measured gene activity after one night, not health outcomes.[35] Consistent sleep that follows your body clock is sensible signalling maintenance (see circadian rhythms).

Diet shapes the secretory environment. Caloric restriction and intermittent fasting are among the interventions that act on the cell's nutrient-sensing growth pathways, the same pathways the drug rapamycin turns down to boost autophagy, the cell's own debris clearance.[36] The human evidence for those approaches is under fasting or caloric restriction. Blood measurements back the direction for diet more broadly: across 33 randomised trials in adults, a Mediterranean pattern lowered high-sensitivity C-reactive protein and interleukin-6 compared with control diets, though it did not significantly change standard C-reactive protein or TNF-alpha, and the authors call for better-quality trials.[37] In the two-year CALERIE trial of 218 healthy, non-obese adults aged 20 to 50, those assigned to cut calories by a quarter lost about 10% of their body weight and ended with C-reactive protein about 40% lower and TNF-alpha about 50% lower than the group eating normally, without weakening their vaccine responses.[38] What that trial and others found for senescent cells themselves is covered under cellular senescence.

The therapeutic frontier

Weak — and a Caution. Everything below is investigational for healthy adults. The plasma-exchange trial in healthy adults was run in part by people with a commercial interest in the procedure. The senolytic evidence has moved past uncontrolled pilots, but only just: the few randomised trials are small, were run in narrow groups such as postmenopausal women or people with fatty-liver disease rather than in healthy aging, and are mixed.

Two strategies aim directly at the signalling problem.

Senolytics and senomorphics clear or quiet the senescent cells that generate the noise. The most-studied combination is dasatinib plus quercetin, and the natural flavonoid fisetin is close behind. The Alzheimer's pilot SToMP-AD (Senolytic Therapy to Modulate the Progression of Alzheimer's Disease) is the trial usually cited for "senolytics reach the brain," and it does show that — but it enrolled five participants, was open-label with no control group, and the drug that reached the cerebrospinal fluid was dasatinib in four of the five; quercetin was never detected there at all. Cognitive and imaging endpoints did not change, which the authors report as evidence of safety rather than benefit. Two markers in the spinal fluid rose: the inflammatory signal interleukin-6 and glial fibrillary acidic protein (GFAP), a sign of activated support cells in the brain. The authors say this could mean senescent cells were being cleared, or simply that the drugs triggered inflammation, and that later samples would be needed to tell which. Two of its authors hold senolytic patents with royalties paid by a biotechnology company.[39] A separate single-arm pilot in twelve older adults with mild cognitive impairment and slow walking found no significant average change in cognition or in the inflammatory marker TNF-alpha. People whose TNF-alpha dropped more tended to gain more on a cognitive test, a pattern the authors themselves call preliminary because there was no control group; its numbers are under cellular senescence.[40] The placebo-controlled follow-up to SToMP-AD, with about 48 participants, has not yet reported.[41] Two randomised trials of the same drug pair outside the brain have. In 60 postmenopausal women it did not reduce the main blood marker of bone breakdown.[42] In 31 adults with scarring fatty-liver disease, about half the treated group showed less liver scarring on biopsy, against one in fourteen on placebo; side effects were more common, though all passed on their own, and the authors treat the result as preliminary until a larger trial repeats it. Two of the authors have a financial interest in senolytic patents.[43]

Animal work on still-earlier ideas is promising and far from the clinic. High-dose intravenous fisetin reduced the number of senescent cells in parts of the brain in six aged sheep, compared with six untreated sheep, a dose and route very different from an oral supplement.[44] A seno-antigen vaccine, which trains the immune system to recognise a surface protein displayed by senescent cells, extended survival in male mice with a model of progeria, a genetic accelerated-aging disease.[45] A later nanoparticle vaccine aimed at the same protein improved fat-tissue metabolism and heart function in mice fed a high-fat diet, and raised their median survival from about 87 to 101 weeks in groups of twelve.[46] These are real lifespan results, but in accelerated-aging or diet-stressed mice rather than normally aged animals, and nothing like them has been tested in people. The site's pharmacology coverage sits under geroprotectors.

Therapeutic plasma exchange attacks the circulating environment directly: a portion of the patient's plasma is removed and replaced with an albumin solution, diluting the pro-aging factors that the parabiosis work implicated. A single-blind, sham-controlled trial in 42 adults over 50, assigned in order of sign-up rather than truly at random, tested three schedules against a sham procedure, reading out 36 DNA-methylation "clocks." Midway through, fifteen of the 36 showed rejuvenation relative to sham, and the strongest arm — plasma exchange every two weeks combined with intravenous immunoglobulin — averaged a 2.6-year reduction in estimated biological age; the sham arm moved on none of the clocks. By the end of the study the difference from sham had disappeared, and no health outcomes were measured.[47]

Four things belong with that number. The outcome is a clock estimate, not a health outcome — nobody lived longer or got measurably better. Most of the movement happened between the first two measurements and had faded by the third, where no group differed from sham. An exploratory analysis hinted that people whose routine blood tests sat at the less healthy end of the normal range, such as higher glucose or lower calcium, showed the biggest clock changes, and the authors lean toward poorer health predicting more benefit. But other markers pointed the other way, every participant's values were within the normal range, and each group held only about eleven people. And several authors co-founded or belong to the company that sells it. The authors themselves call the trial hypothesis-generating rather than definitive. Interesting proof-of-concept; not a healthy-adult intervention.

An independent trial points the other way. In 34 healthy first-time plasma donors aged 40 to 60, removing plasma four or eight times over 18 weeks without replacing it, as in routine plasma donation, made no epigenetic clock look younger; three aging measures moved slightly in the older direction, which the authors suggest may be a stress response to the procedure.[48] That procedure is not the same as plasma exchange with albumin, but together the two results show how easily these clocks move, in either direction. The one large randomised test of plasma exchange against an age-related disease was in 347 people with mild-to-moderate Alzheimer's: about 14 months of treatment slowed the loss of everyday-living abilities by about half compared with sham, memory and thinking scores fell just short of significance, the benefit was seen in people at the moderate stage but not the mild one, and the albumin maker sponsored it.[49] Neither is the same as the commercial "young plasma" infusions, which have no proven benefit (see plasma exchange).

What this does and doesn't tell you

What it tells you: altered intercellular communication is the hallmark that explains how aging becomes systemic. Senescent-cell secretions, decaying physical channels, a stiffening matrix, pro-aging blood factors and a drifting neuroendocrine clock together convert local damage into body-wide decline. The blood-exchange experiments are genuinely striking evidence that aging is in part a signalling state and not just accumulated wear — and they show the pro-aging direction is the stronger one. The levers that quiet the noise are the familiar ones: exercise, which modestly lowers some inflammatory markers in trials; an anti-inflammatory diet, with similar trial support; and aligned sleep, where the human evidence is thinner. The observational data say the gap between doing all three well and doing none of them well is on the order of nine years of healthy life, and that moving off the floor takes remarkably little.

What it doesn't tell you: that any clinic-ready therapy reverses it. Senolytics, seno-vaccines and plasma exchange are mechanistically exciting and backed by animal models and mostly small human trials — the plasma-exchange result, read carefully, moves a surrogate marker, may help the less healthy more in an exploratory analysis, had faded by the end of the study, and comes from investigators with a stake in the procedure; an independent plasma-removal trial moved the clocks the other way. Hormonal optimisation has a real role, but only where clinically indicated. And the lifestyle evidence is mixed in kind: trials show exercise and diet lower some inflammatory markers modestly, and observational data tie these behaviours to a long healthy life, but no trial shows that any of them repairs a specific signalling channel or slows aging itself. The durable message is the recurring one across this site — the reliable way to keep your cells talking clearly is to move, sleep and eat in the ways that lower systemic inflammation.

Further reading

  • Sanada F, et al. Targeting the hallmarks of aging: mechanisms and therapeutic opportunities. Front Cardiovasc Med 2025.[50]
  • López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. Hallmarks of aging: An expanding universe. Cell 2023.[51]
  • De Luca F, et al. From Senescent Cells to Systemic Inflammation: The Role of Inflammaging in Age-Related Diseases and Kidney Dysfunction. Cells 2025.[52]
  • Aamir SW, et al. Extracellular Vesicles as Key SASP Carriers Driving Cellular Senescence, Inflammaging, and Therapeutic Opportunities in Aging and Age-Related Diseases. Aging Dis 2026.[53]
  • Genetos DC, et al. Age-related changes in gap junctional intercellular communication in osteoblastic cells. J Orthop Res 2012.[54]
  • Ariazi J, et al. Tunneling Nanotubes and Gap Junctions–Their Role in Long-Range Intercellular Communication during Development, Health, and Disease Conditions. Front Mol Neurosci 2017.[55]
  • Zhang B, et al. Multi-omic rejuvenation and life span extension on exposure to youthful circulation. Nat Aging 2023 — mice.[56]
  • Rebo J, Mehdipour M, Conboy MJ, Conboy IM, et al. A single heterochronic blood exchange reveals rapid inhibition of multiple tissues by old blood. Nat Commun 2016.[57]
  • Zhang G, Li J, Purkayastha S, et al. Hypothalamic programming of systemic ageing involving IKK-β, NF-κB and GnRH. Nature 2013 — mice.[58]
  • Skrapits K, et al. The cryptic gonadotropin-releasing hormone neuronal system of human basal ganglia. Elife 2021.[59]
  • Masliukov PM. Changes of Signaling Pathways in Hypothalamic Neurons with Aging. Curr Issues Mol Biol 2023.[60]
  • Veldhuis JD. Changes in pituitary function with ageing and implications for patient care. Nat Rev Endocrinol 2013.[61]
  • Chow LS, et al. Exerkines in health, resilience and disease. Nat Rev Endocrinol 2022.[62]
  • Qiu Y, et al. Exercise sustains the hallmarks of health. J Sport Health Sci 2023.[63]
  • Chini CCS, Cordeiro HS, et al. NAD metabolism: Role in senescence regulation and aging. Aging Cell 2024.[64]
  • Koemel NA, Biswas RK, Ahmadi MN, et al. Minimum combined sleep, physical activity, and nutrition variations associated with lifeSPAN and healthSPAN improvements: a population cohort study. eClinicalMedicine 2026 — UK Biobank, n=59,078.[65]
  • Gonzales MM, Garbarino VR, Orr ME, et al. Senolytic therapy in mild Alzheimer's disease: a phase 1 feasibility trial. Nat Med 2023 — SToMP-AD; open-label, n=5.[66]
  • Millar CL, et al. A pilot study of senolytics to improve cognition and mobility in older adults at risk for Alzheimer's disease. EBioMedicine 2025 — single-arm, open-label, n=12.[67]
  • Farr JN, et al. Effects of intermittent senolytic therapy on bone metabolism in postmenopausal women: a phase 2 randomized controlled trial. Nat Med 2024 — n=60.[68]
  • Suda M, Shimizu I, Minamino T, et al. Senolytic vaccination improves normal and pathological age-related phenotypes and increases lifespan in progeroid mice. Nature Aging 2021.[69]
  • Fuentealba M, Kiprov D, Verdin E, Furman D, et al. Multi-Omics Analysis Reveals Biomarkers That Contribute to Biological Age Rejuvenation in Response to Single-Blinded Randomized Placebo-Controlled Therapeutic Plasma Exchange. Aging Cell 2025 — n=42; author conflicts disclosed.[70]
  • Borsky P, et al. Human clinical trial of plasmapheresis effects on biomarkers of aging (efficacy and safety trial). Sci Rep 2025 — n=34, no rejuvenation.[71]

— § —